title: Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy.
abstract: Cardiac hypertrophy is a major cause of morbidity and mortality worldwide. The hypertrophic process is mediated, in part, by small G proteins of the Rho family. We hypothesized that statins, inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase, inhibit cardiac hypertrophy by blocking Rho isoprenylation. We treated neonatal rat cardiac myocytes with angiotensin II (AngII) with and without simvastatin (Sim) and found that Sim decreased AngII-induced protein content, [3H] leucine uptake, and atrial natriuretic factor (ANF) promoter activity. These effects were associated with decreases in cell size, membrane Rho activity, superoxide anion (O2*-) production, and intracellular oxidation, and were reversed with L-mevalonate or geranylgeranylpyrophosphate, but not with farnesylpyrophosphate or cholesterol. Treatments with the Rho inhibitor C3 exotoxin and with cell-permeable superoxide dismutase also decreased AngII-induced O2*- production and myocyte hypertrophy. Overexpression of the dominant-negative Rho mutant N17Rac1 completely inhibited AngII-induced intracellular oxidation and ANF promoter activity, while N19RhoA partially inhibited it, and N17Cdc42 had no effect. Indeed, Sim inhibited cardiac hypertrophy and decreased myocardial Rac1 activity and O2*- production in rats treated with AngII infusion or subjected to transaortic constriction. These findings suggest that statins prevent the development of cardiac hypertrophy through an antioxidant mechanism involving inhibition of Rac1.
authors.affiliation: Vascular Medicine Unit, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.
authors.forename: M
authors.initials: M
authors.lastname: Takemoto
authors.forename: K
authors.initials: K
authors.lastname: Node
authors.forename: H
authors.initials: H
authors.lastname: Nakagami
authors.forename: Y
authors.initials: Y
authors.lastname: Liao
authors.forename: M
authors.initials: M
authors.lastname: Grimm
authors.forename: Y
authors.initials: Y
authors.lastname: Takemoto
authors.forename: M
authors.initials: M
authors.lastname: Kitakaze
authors.forename: J K
authors.initials: JK
authors.lastname: Liao
mesh_terms: D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D009320:Atrial Natriuretic Factor / Q000235:genetics; D006332:Cardiomegaly / Q000517:prevention & control*; D002478:Cells, Cultured; D006321:Heart / Q000187:drug effects; D051379:Mice; D009206:Myocardium / Q000378:metabolism*; D010084:Oxidation-Reduction; D011401:Promoter Regions, Genetic; D051381:Rats; D017207:Rats, Sprague-Dawley; D019821:Simvastatin / Q000494:pharmacology*; D013481:Superoxides / Q000378:metabolism; D020830:rac1 GTP-Binding Protein / Q000502:physiology
chemical_list: D000975:Antioxidants; D013481:Superoxides; D000804:Angiotensin II; D009320:Atrial Natriuretic Factor; D019821:Simvastatin; D020830:rac1 GTP-Binding Protein